We are live on ! Find out more
ZVSA

ZyVersa Therapeutics
ZVSA

Delisted

ZVSA was delisted on the 16th of July, 2025.

Back to rankings

6 hedge funds and large institutions have $44.7K invested in ZyVersa Therapeutics in 2025 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% more capital invested

Capital invested by funds: $43.9K → $44.7K (+$813)

1.33% less ownership

Funds ownership: 2.72% → 1.38% (-1.3%)

14% less funds holding

Funds holding: 7 → 6 (-1)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.08%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
4
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
+$7.16K
2
TRCT
Tower Research Capital (TRC)
New York
+$1.55K
3
Citigroup
Citigroup
New York
+$179
4
SS
SBI Securities
Japan
+$66
5
Bank of America
Bank of America
North Carolina
+$14

Top Sellers

Rank Fund Capital Flow
1
VF
Virtu Financial
New York
-$11K
2
Morgan Stanley
Morgan Stanley
New York
-$1

ZVSA Hedge Fund Activity: Q2 2025 in Review

6 of the 7,612 institutional investors tracked by Wall St. Rank reported a position in ZyVersa Therapeutics (ZVSA) for Q2 2025, worth a combined $44.7K — up 1.9% from $43.9K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of ZVSA and 1 opened new positions — a net loss of 1 holder — while 0 trimmed existing stakes and 4 added.

The largest buyer was UBS Group, adding an estimated $7.16K. The largest seller was Virtu Financial, exiting entirely with an estimated $11K sold.

  • 6 institutional investors held ZyVersa Therapeutics (ZVSA) as of Q2 2025, down from 7 in Q1 2025.
  • Funds reported $44.7K of ZyVersa Therapeutics stock for Q2 2025, up 1.9% quarter-over-quarter.
  • 1 fund opened new ZyVersa Therapeutics positions in Q2 2025 and 2 closed out, a net change of -1 holder.
  • The largest ZyVersa Therapeutics buyer in Q2 2025 was UBS Group, an estimated $7.16K added.
  • The largest ZyVersa Therapeutics seller in Q2 2025 was Virtu Financial, an estimated $11K sold.

Based on aggregated 13F filings for Q2 2025.